• FDA Risk Communication Advisory Committee Proposes New Standardized Template for FDA Press Releases Announcing Product Recalls
  • March 18, 2010 | Authors: Edward M. Basile; Christina M. Markus; Elaine H. Tseng
  • Law Firms: King & Spalding LLP - Washington Office ; King & Spalding LLP - San Francisco Office ; King & Spalding LLP - Washington Office ; King & Spalding LLP - San Francisco Office
  • On February 25 and 26, 2010, the Risk Communication Advisory Committee of the U.S. Food & Drug Administration (FDA RCAC) held a public meeting to discuss strategies for improving postmarket safety communications to health care providers, patients, and the general public. The meeting, which was chaired by Nancy M. Ostrove, PhD, FDA Director for Risk Communication, focused broadly on risk communication related to drugs, biologics, medical devices, and veterinary medicines. The meeting examined the clarity and effectiveness of recent FDA postmarket safety communications. For illustrative purposes, the examples included FDA communications relating to external cardiac defibrillators, multislice CT scanning systems, several prescription drugs, vaccines, and veterinary pain medication.